Biopico Systems

Executive Summary

Biopico Systems is advancing preclinical drug development with its OrganRX™ platform, a suite of human-relevant multiorgan models designed to improve predictive accuracy for next-generation therapies, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. The core product, the OrganRX™ Plate, is a polystyrene injection-molded disposable plate with a glass bottom, featuring six units that co-culture multiple organ-specific cells to recapitulate human physiology. By enabling more physiologically relevant testing, Biopico aims to reduce the high failure rates of drugs in clinical trials, particularly for biologics and complex modalities. Founded in 2009 and headquartered in Irvine, California, the company operates at the preclinical stage and targets the lab automation, microfluidics, and diagnostics markets. Despite limited public information on funding or valuation, Biopico's technology addresses a critical unmet need in drug development: the lack of predictive human models that can replace animal testing and better forecast clinical outcomes. The OrganRX™ Tissue Plate, pre-seeded with cells, offers a ready-to-use solution for pharmaceutical companies seeking to de-risk their pipelines. As the industry shifts toward more ethical and accurate preclinical tools, Biopico is well-positioned to capture market share in the organ-on-a-chip and microphysiological systems space. However, the company faces competition from established players like Emulate and Mimetas, and its success depends on widespread adoption by top pharma firms. Key upcoming catalysts include potential partnerships with large pharmaceutical companies, securing Series A funding to scale manufacturing, and regulatory endorsements from the FDA for alternative testing methods. With the growing push for drug development efficiency and animal testing alternatives, Biopico's human-relevant models could become a standard tool in preclinical assessment, making it a compelling early-stage investment opportunity.

Upcoming Catalysts (preview)

• Q3 2026Pharmaceutical Partnership or Licensing Deal50% success
• Q4 2026Series A Funding Round40% success
• TBDFDA Endorsement of OrganRX for Preclinical Studies30% success